Dexcom/TypeZero, 946 Grady Avenue, Suite 203, Charlottesville, VA 22903, United States of America.
Dexcom/TypeZero, 946 Grady Avenue, Suite 203, Charlottesville, VA 22903, United States of America.
Metabolism. 2021 Nov;124:154872. doi: 10.1016/j.metabol.2021.154872. Epub 2021 Sep 1.
Artificial intelligence (AI) is widely discussed in the popular literature and is portrayed as impacting many aspects of human life, both in and out of the workplace. The potential for revolutionizing healthcare is significant because of the availability of increasingly powerful computational platforms and methods, along with increasingly informative sources of patient data, both in and out of clinical settings. This review aims to provide a realistic assessment of the potential for AI in understanding and managing diabetes, accounting for the state of the art in the methodology and medical devices that collect data, process data, and act accordingly. Acknowledging that many conflicting definitions of AI have been put forth, this article attempts to characterize the main elements of the field as they relate to diabetes, identifying the main perspectives and methods that can (i) affect basic understanding of the disease, (ii) affect understanding of risk factors (genetic, clinical, and behavioral) of diabetes development, (iii) improve diagnosis, (iv) improve understanding of the arc of disease (progression and personal/societal impact), and finally (v) improve treatment.
人工智能(AI)在大众文学中被广泛讨论,被描绘为影响人类生活的方方面面,无论是在工作场所内外。由于越来越强大的计算平台和方法的可用性,以及越来越多的患者数据来源,无论是在临床环境内还是外,人工智能在医疗保健领域具有重大的变革潜力。本综述旨在对 AI 在理解和管理糖尿病方面的潜力进行现实评估,同时考虑到用于收集、处理和相应地采取行动的数据的方法和医疗设备的现状。鉴于已经提出了许多相互矛盾的 AI 定义,本文试图将该领域的主要元素与糖尿病联系起来,确定可以(i)影响对疾病的基本理解、(ii)影响对糖尿病发展的风险因素(遗传、临床和行为)的理解、(iii)改善诊断、(iv)改善对疾病进程(进展和个人/社会影响)的理解,以及最终(v)改善治疗的主要观点和方法。